We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens (WBA) Inks Deal to Expand COVID-19 Testing Access
Read MoreHide Full Article
Walgreens Boots Alliance, Inc. (WBA - Free Report) recently inked a deal with Abbott Laboratories (ABT - Free Report) to sell Abbott’s BinaxNOW Rapid Antigen Self Test over-the-counter nationwide at Walgreens stores. The agreement is part of Walgreens’ continued efforts to increase access to COVID-19 testing across the United States.
Walgreens is one of the first mass retailers to make Abbott’s test widely available. The test received the FDA’s emergency use authorization for over-the counter, non-prescription, asymptomatic use of the BinaxNOW Self Test for the detection of COVID-19 infection on Mar 31, 2021.
With the expansion of access to COVID-19 testing solutions, Walgreens continues to play a vital role in the nation’s pandemic response efforts.
BinaxNOW Rapid Antigen Self Test at a Glance
BinaxNOW by Abbott is a lateral flow immunoassay proposed for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 infection.
This self-test version of BinaxNOW allows users to self-administer the test collection using a short nasal swab rather than the deep and invasive nasopharyngeal swab. The results are available in 15 minutes.
More in the News
Despite the wide availability of vaccines, COVID-19 testing remains a vital tool to keep communities safe. Walgreens has taken a significant step to increase testing capacity at more than 5,500 Walgreens pharmacies and is also planning to expand testing to 6,000 drive-thru testing sites with half of these sites offering the no-cost, rapid Abbott ID NOW COVID-19 test.
The addition of this rapid antigen over-the-counter test in-store will help customers gain access to testing solutions when and how they need it — at home or at one of the company’s conveniently-located testing sites. The BinaxNOW Self Test paves the way for Americans to get an accurate and affordable test on their own terms, as and when required.
COVID-Related Developments by Walgreens
In February 2021, Walgreens entered into an agreement with Labcorp to sell Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over the counter at up to 6,000 Walgreens stores nationwide, starting spring 2021. The addition of this collection kit in-store will enable customers to have access to testing solutions as and when needed – at home, in store or at one of Walgreens’ other conveniently-located testing sites.
During the same month, Walgreens announced that Clinical Reference Laboratory makes the FDA-authorized CRL Rapid Response COVID-19 Saliva Test available through Walgreens Find Care. Using Walgreens Find Care, individuals can connect with CRL’s website to order the test if they meet one or more of the clinical guidelines for COVID-19 testing by completing a short online questionnaire.
Industry Prospects
Per Grand View Research, the global COVID-19 diagnostics market size was valued $84.4 billion in 2020 and is expected to see a CAGR of 3.1% by 2027.
Considering market growth, Walgreens’ continued efforts to expand its COVID-19 testing solution are well-timed.
Price Performance
Shares of the company have gained 25.5% in a year’s time compared with the industry’s growth of 27.7%.
Zacks Rank and Key Picks
Currently, Walgreens carries a Zacks Rank #3 (Hold).
Cantel Medical has an estimated long-term earnings growth rate of 19%.
ConforMIS has a projected long-term earnings growth rate of 42%.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Image: Bigstock
Walgreens (WBA) Inks Deal to Expand COVID-19 Testing Access
Walgreens Boots Alliance, Inc. (WBA - Free Report) recently inked a deal with Abbott Laboratories (ABT - Free Report) to sell Abbott’s BinaxNOW Rapid Antigen Self Test over-the-counter nationwide at Walgreens stores. The agreement is part of Walgreens’ continued efforts to increase access to COVID-19 testing across the United States.
Walgreens is one of the first mass retailers to make Abbott’s test widely available. The test received the FDA’s emergency use authorization for over-the counter, non-prescription, asymptomatic use of the BinaxNOW Self Test for the detection of COVID-19 infection on Mar 31, 2021.
With the expansion of access to COVID-19 testing solutions, Walgreens continues to play a vital role in the nation’s pandemic response efforts.
BinaxNOW Rapid Antigen Self Test at a Glance
BinaxNOW by Abbott is a lateral flow immunoassay proposed for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 infection.
This self-test version of BinaxNOW allows users to self-administer the test collection using a short nasal swab rather than the deep and invasive nasopharyngeal swab. The results are available in 15 minutes.
More in the News
Despite the wide availability of vaccines, COVID-19 testing remains a vital tool to keep communities safe. Walgreens has taken a significant step to increase testing capacity at more than 5,500 Walgreens pharmacies and is also planning to expand testing to 6,000 drive-thru testing sites with half of these sites offering the no-cost, rapid Abbott ID NOW COVID-19 test.
The addition of this rapid antigen over-the-counter test in-store will help customers gain access to testing solutions when and how they need it — at home or at one of the company’s conveniently-located testing sites. The BinaxNOW Self Test paves the way for Americans to get an accurate and affordable test on their own terms, as and when required.
COVID-Related Developments by Walgreens
In February 2021, Walgreens entered into an agreement with Labcorp to sell Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over the counter at up to 6,000 Walgreens stores nationwide, starting spring 2021. The addition of this collection kit in-store will enable customers to have access to testing solutions as and when needed – at home, in store or at one of Walgreens’ other conveniently-located testing sites.
During the same month, Walgreens announced that Clinical Reference Laboratory makes the FDA-authorized CRL Rapid Response COVID-19 Saliva Test available through Walgreens Find Care. Using Walgreens Find Care, individuals can connect with CRL’s website to order the test if they meet one or more of the clinical guidelines for COVID-19 testing by completing a short online questionnaire.
Industry Prospects
Per Grand View Research, the global COVID-19 diagnostics market size was valued $84.4 billion in 2020 and is expected to see a CAGR of 3.1% by 2027.
Considering market growth, Walgreens’ continued efforts to expand its COVID-19 testing solution are well-timed.
Price Performance
Shares of the company have gained 25.5% in a year’s time compared with the industry’s growth of 27.7%.
Zacks Rank and Key Picks
Currently, Walgreens carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space include Cantel Medical Corp. and ConforMIS, Inc. , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cantel Medical has an estimated long-term earnings growth rate of 19%.
ConforMIS has a projected long-term earnings growth rate of 42%.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>